본문 바로가기

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
Cancer Research and Treatment52(1) · pp.277 · 2020
피인용
Web of Science 30Scopus 32KCI 1
FWCI (Scopus)
0
JCR IF
JCR 2019 3.761
ISSN
1598-2998

저자

  1. Lee, Hee Yeon제1저자Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
  2. Hong, Ji HyungDepartment of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
  3. Byun, Jae Ho교신저자Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon
  4. Kim, Hee-JunDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul
  5. Baek, Sun KyungDepartment of Internal Medicine, Kyung Hee University School of Medicine, Seoul
  6. Kim, Jin YoungDepartment of Hemato-Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu
  7. Kim, Ki HyangDepartment of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan
  8. Yun, JinaDepartment of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon
  9. Kim, Jung A.Department of Internal Medicine, Kyung Hee University Gangdong Hospital, Seoul
  10. 박권오Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan
  11. Lee, Hyo JinDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon
  12. Lee, Jung LimDepartment of Hemato-oncology, Daegu Fatima Hospital, Daegu
  13. Won, Young-WoongDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul
  14. Kim, Il HwanDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan
  15. Bae, Woo KyunDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun
  16. Park, Kyong HwaDepartment of Internal Medicine, Korea University College of Medicine, Seoul
  17. Sun, Der-ShengDepartment of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu
  18. Lee, SueeDepartment of Internal Medicine, Dong-A University Hospital, Busan
  19. Lee, Min-YoungDepartment of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul
  20. Lee, Guk JinDepartment of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon
  21. Hong, Sook HeeDepartment of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
  22. Jung, Yun HwaSun General Hospital, Daejeon
  23. An, Ho JungDepartment of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea

초록

Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease <= 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

키워드

Ovarian epithelial carcinomaClear cell adenocarcinomaKoreaAdjuvant chemotherapyPROGRESSION-FREE SURVIVALADJUVANT CHEMOTHERAPYARID1A EXPRESSIONENDOMETRIOSISCARCINOMAMUTATIONSPROGNOSISCOHORTEVENT

식별자

Scopus EID
2-s2.0-85077934315
WoS UID
000507387500024
KCI
ART002549163